MERCK KGAA |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 174 EUR | -1.05% |
|
+1.22% | +20.75% |
| 06-11 | Merck KGaA to Build EUR62 Million Facility for Life Science Business | MT |
| 06-07 | Health Care Up as Defensive Rotation Continues - Health Care Roundup | DJ |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 21.32B 23.06B 1,803B | Sales 2025 * | 22.64B 24.49B 1,915B | Capitalization | 76.46B 82.69B 6,466B |
|---|---|---|---|---|---|
| Net income 2024 * | 3B 3.24B 253B | Net income 2025 * | 3.52B 3.81B 298B | EV / Sales 2024 * | 3.88 x |
| Net Debt 2024 * | 6.19B 6.69B 523B | Net Debt 2025 * | 4.37B 4.73B 370B | EV / Sales 2025 * | 3.57 x |
| P/E ratio 2024 * |
25.6
x | P/E ratio 2025 * |
21.6
x | Employees | 62,345 |
| Yield 2024 * |
1.32% | Yield 2025 * |
1.45% | Free-Float | 29.71% |
More Fundamentals
* Assessed data
More news
Latest transcript on Merck KGaA
More press releases
More news
| 1 day | -1.08% | ||
| 1 week | +1.22% | ||
| Current month | +4.50% | ||
| 1 month | +12.62% | ||
| 3 months | +8.72% | ||
| 6 months | +28.46% | ||
| Current year | +20.75% |
1 week
169.50
176.25
1 month
155.10176.25
Current year
140.50176.25
1 year
134.30176.25
3 years
134.30231.50
5 years
76.22231.50
10 years
61.05231.50
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 62 | 12/07/20 | |
Marcus Kuhnert
DFI | Director of Finance/CFO | 56 | 31/07/14 |
| Director of Finance/CFO | 54 | 25/04/19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 75 | 08/05/14 | |
Christian Raabe
BRD | Director/Board Member | - | - |
| Chairman | 67 | 25/04/19 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.34% | 2 M€ | +13.56% | - | |
| 1.80% | 962 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/06/24 | 174 | -1.05% | 8 547 |
| 12/06/24 | 175.8 | +2.36% | 344,307 |
| 11/06/24 | 171.8 | -0.06% | 198,209 |
| 10/06/24 | 171.9 | +0.35% | 151,028 |
| 07/06/24 | 171.3 | -0.35% | 140,012 |
Delayed Quote Xetra, June 13, 2024 at 08:52 am
More quotes
Merck KGaA is one of the world's leading pharmaceutical and chemical groups. Net sales break down by family of products as follows:
- solutions and products for scientific and biotechnological research (44.2%);
- pharmaceutical products (38.4%): prescription drugs for the treatment of diabetes, cancer, multiple sclerosis, infertility, cardiovascular disease, central nervous system disorders, inflammatory disorders, etc.;
- performance materials for the electronics industry (17.4%): semiconductor materials, liquid crystals, pigments and additives, carbon-based organic materials, etc.
Net sales are distributed geographically as follows: Germany (4.8%), Europe (24%), China (12.9%), Asia/Pacific (20.1%), the United States (26.8%), North America (1.6%), Latin America (6.3%), Middle East and Africa (3.5%).
Sector
Pharmaceuticals
Calendar
31/07/2024
- Q2 2024 Earnings Call
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A
Sell
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
175.8
EUR
Average target price
186.1
EUR
Spread / Average Target
+5.81%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +20.75% | 82.93B | |
| +13.33% | 9.15B | |
| +48.35% | 4.65B | |
| -20.52% | 4.58B | |
| +7.99% | 4.07B | |
| +9.70% | 2.24B | |
| -25.72% | 2.21B | |
| +12.16% | 2.03B | |
| -41.98% | 1.82B | |
| -0.50% | 1.64B |
- Stock Market
- Equities
- MRK Stock